Xeglyze FDA Approval History
Last updated by Judith Stewart, BPharm on July 31, 2020.
FDA Approved: Yes (First approved July 24, 2020)
Brand name: Xeglyze
Generic name: abametapir
Dosage form: Topical Lotion
Company: Dr. Reddy's Laboratories, Inc.
Treatment for: Head Lice
Xeglyze (abametapir) is a pediculicide indicated for the topical treatment of head lice infestation in patients 6 months of age and older.
- Xeglyze should be used as part of an overall lice management program which includes washing (with hot water) or dry-cleaning all recently worn clothing, hats, used bedding and towels; washing ((with hot water) personal care items such as combs, brushes and hair clips; and using a fine-tooth comb or special nit comb to remove dead lice and nits.
- Xeglyze is applied to dry hair to thoroughly coat the hair and scalp. Xeglyze should be massaged into the hair and scalp, then left on for 10 minutes before rinsing off with warm water.
- Common adverse reactions include erythema, rash, skin burning sensation, contact dermatitis, vomiting, eye irritation, pruritus, and hair color changes.
Development timeline for Xeglyze
| Date | Article |
|---|---|
| Jul 27, 2020 | Approval FDA Approves Xeglyze (abametapir) Lotion for the Treatment of Head Lice |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.